CereMark Pharma

Executive Summary

CereMark Pharma, a Boston-based biotech founded in 2017, is pioneering novel PET imaging radiopharmaceuticals for neurodegenerative diseases. Its lead candidate, F-18 Flornaptitril (F-18 FNT), uniquely visualizes both tau and beta-amyloid pathology in living brains, potentially enabling earlier and more accurate diagnosis of Alzheimer's disease and chronic traumatic encephalopathy. The company's dual-target approach could improve patient stratification and treatment monitoring, addressing a critical unmet need as disease-modifying therapies emerge. Currently private and in preclinical/early clinical stages, CereMark's progress depends on successful imaging agent validation and regulatory milestones.

Upcoming Catalysts (preview)

• Q4 2026Initiation of Phase 1/2 clinical trial for F-18 Flornaptitril70% success
• Q2 2026Presentation of preclinical validation data at a major neurology conference85% success
• Q1 2027Potential partnership with a large pharma or CRO for development and commercialization50% success